home / stock / rvlp / rvlp news

RVLP News and Press, RVL Pharmaceuticals plc From 03/30/22

Stock Information
Company Name: RVL Pharmaceuticals plc
Stock Symbol: RVLP
Market: NASDAQ
Menu
RVLP RVLP Quote RVLP Short RVLP News RVLP Articles RVLP Message Board
Get RVLP Alerts

News, Short Squeeze, Breakout and More Instantly...
RVLP - RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Hapless Osmotica renamed itself RVL Pharmaceuticals. It has a novel business model which vastly simplifies its business. Encouragingly, recent company estimate pegs 2022 Q4 UPNEEQ net revenues at $20-$25 million. For further details see: RVL Pharmaceuticals: A Makeover F...
RVLP - RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch

BRIDGEWATER, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 fourth quarter and full year financial results and pr...

RVLP - RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022

BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operati...

RVLP - UPDATE - Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in...
RVLP - Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in...

Previous 10 Next 10